Article Text

Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area
Free
  1. Rim Bourguiba1,
  2. Marion Delplanque1,
  3. Caroline Vinit2,
  4. Felix Ackermann3,
  5. Léa Savey1,
  6. Gilles Grateau1,
  7. Veronique Hentgen2,
  8. Sophie Georgin-lavialle1
  1. 1Sorbonne Université, AP-HP, DMU3ID, Tenon hospital, Internal medicine department, national reference center of autoinflammatory diseases and inflammatory amyloidosis (CEREMAIA), Paris, France
  2. 2General pediatry department, Versaille hospital, André-Mignot, General pediatry department, National reference center of autoinflammatory diseases and inflammatory amyloidosis (CEREMAIA), versailles, France
  3. 3Department of Internal Medicine, Hopital Foch, Sursennes, France
  1. Correspondence to Professor Sophie Georgin-lavialle, Tenon Hospital, Internal Medicine, AP-HP, Paris 75020, France; sophie.georgin-lavialle{at}aphp.fr

Statistics from Altmetric.com

The novel COVID-19 pandemic caused by SARS-CoV-2 is responsible for many deaths worldwide. Severe or life-threatening disease induce an exaggerated inflammatory response known as the ‘cytokine storm’, raising the question of the susceptibility and severity of SARS-CoV-2 infection in patients displaying innate immunity disorders such as familial Mediterranean fever (FMF). Furthermore, FMF patients take a long-term therapy with colchicine, which has been tested in SARS-CoV-2-infected patients with conflicting results.1

To tackle this question, we conducted a survey on SARS-CoV-2 infection in FMF patients followed in Paris area. In that meantime, the official French rate of infection in Paris area was 11% of the whole population.2 FMF patients were identified from the juvenile inflammatory rheumatism (JIR) cohort, an international multicenter data repository and consented to the study. For the purpose of the study, we included only patients fulfilling the international FMF criteria, with a genetic confirmed FMF diagnosis,3 and followed up in the French national autoinflammatory centre in Paris area.

Identified patients (n=627) were invited to answer a short questionnaire in consultation by phone or email about a possible SARS-CoV-2 infection during the time span ranging from March until end of May 2020; 342 patients answered the survey SARS-CoV-2 infection, diagnosis had been retained if the patient displayed clinical symptoms with a positive SARS-CoV-2 reverse transcriptase (RT)-PCR or serology or a typical chest CT scan. Overall, 27 FMF patients (7.8% of the responders; sex ratio 1:1) contracted the virus and 315 did not. All but one of the FMF-COVID+ patients were taking daily colchicine since a median time of 23 years, mostly 1 mg/day table 1. Four received in addition an interleukin 1 (IL-1) inhibitor. Clinical symptoms of COVID-19 were consistent with those described previously.4

Table 1

Clinical course of 27 patients displaying COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area

Out of the 27 FMF-COVID+ patients, 7 patients were admitted in hospital (25%), displayed and six required oxygen therapy 3 (11%) developed acute respiratory distress syndrome and went to intensive care unit for mechanical ventilation and haemodialysis (online supplemental table). Two patients died (7%) but had respectively three and four comorbidities for severe SARS-CoV-2 infection (see online supplemental table). The third patient, 40 years old, suffered from hypertension and obesity. Patient older than 65 years accounted for 17% of the whole cohort, 75% were hospitalised and required oxygen; one died. Out of the three AA amyloidosis patients, two were hospitalised and one died. No additional antiviral treatment was administrated. At the end of the first epidemic wave in Paris area, the five survivors after hospitalisation went back home. None of them showed clinical signs of FMF attacks during SARS-CoV-2 infection.

The profile of our patients with a severe or life-threatening SARS-CoV-2 infection was like the general population. Severe SARS-CoV-2 infection was seen only in patients displaying known risk factors such as advanced age, chronic kidney disease, hypertension, vascular disease obesity and lung dysfunction. Our study suggests that the dysfunction of the innate immune system of FMF does not seem to be a risk factor in itself. However, preventive effect of long-term colchicine intake cannot be concluded as it was reported in a large cohort of patients with continuous colchicine therapy.1

Here, two out of four SARS-CoV-2-infected-FMF patients receiving IL-1 inhibitors died; of note, such patients usually display more advanced FMF including AA amyloidosis. Our study design did not allow us to conclude as to the responsibility of the drug or the underlying condition in this particular observation, despite recent publications showing efficacy of anakinra in severe SARS-CoV-2 infection.5 None of the non-infected-FMF patients died in the same period. Notwithstanding, our preliminary conclusion is that FMF patients receiving a long-term treatment with daily colchicine have no additional risk factor for severe SARS-CoV-2 infection compared with the general population.

Acknowledgments

Pr Thomas Hanslik and Dr Philippe Evon.

References

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • Handling editor Josef S Smolen

  • Twitter @Rimbourguiba1, @SophieGeorgin

  • RB and MD contributed equally.

  • Correction notice This article has been corrected since it published Online First. The author, Dr Ackermann, has been added to the author list.

  • Contributors All Authors contributed in writing the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethics approval This observational study was based on data extracted from the Juvenile inflammatory Rheumatism (JIR) cohort, an international multicenter data repository established by the National Commission on Informatics and Liberty.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.